

Coccidioidomycosis (Valley Fever): Considerations for Development of Antifungal Drugs —August 5, 2020

Speakers and Panelists: Affiliations and Disclosures

Neil M. Ampel, MD

Professor Emeritus of Medicine and Immunobiology, University of Arizona
Supplemental Consultant, Mayo Clinic in Arizona
President, Coccidioidomycosis Study Group
Tucson, AZ

David Angulo, MD

Chief Medical Officer
Scynexis, Inc.
Jersey City, NJ

Bridget Marie Barker, PhD

Associate Professor
Director NAU ABSL3
Pathogen and Microbiome Institute
Northern Arizona University
Flagstaff AZ

John Bennett, MD

Senior Investigator
Clinical Mycology Section
NIAID, NIH
Bethesda, MD

Janis E. Blair, MD

Consultant, Division of Infectious Diseases
Professor of Medicine
Mayo Clinic
Phoenix, AZ

Antonino Catanzaro, MD

Professor of Medicine
University of California, San Diego
La Jolla, CA

Tom M. Chiller, MD, MPHTM

Chief, Mycotic Diseases Branch
Associate Director of Global Programs
Division of Foodborne, Waterborne, and Environmental Diseases
Nation Center for Emerging and Zoonotic Infectious Diseases
Centers for Disease Control and Prevention
Atlanta, GA

Cheryl Dixon, PhD

Statistical Reviewer
Division of Biometrics IV (DBIV), Office of Translational Sciences (OTS)
CDER, FDA
Silver Spring, MD

Dennis M. Dixon, PhD

Chief, Bacteriology and Mycology Branch
Division of Microbiology and Infectious Diseases
HHS/NIH/NIAID
Bethesda, MD

Erica Easton

President
Kern Medical Foundation
Bakersfield, CA

David Engelthaler, PhD

Co-Director and Associate Professor
Pathogen Genomics Division
TGen North
Phoenix, AZ

John Farley, MD, MPH

Director
Office of Infectious Diseases (OID)
OND, CDER, FDA
Silver Spring, MD

John Galgiani, MD

Professor, University of Arizona
Colleges of Medicine, Tucson and Phoenix
Director, UA Valley Fever Center for Excellence
Director, Banner University Health Valley Fever Program
Tucson, AZ

Edward Garvey, PhD
Consultant
Mycovia Pharmaceuticals
Durham, NC

Karen Higgins, Sc.D.
Statistical Team Leader
DBIV, OTS
OND, CDER, FDA
Silver Spring, MD

Susan Hoover, MD, PhD
Infectious Disease Group and Sanford Research
Sanford Health
Sioux Falls, SD

William Hope, PhD
Dame Sally Davies Chair of AMR Research
Director, Centre of Excellence in Infectious Diseases Research
Department of Molecular and Clinical Pharmacology
University of Liverpool
United Kingdom

Caroline Jjingo, MD, MPH
Clinical Reviewer
Division of Anti-Infectives (DAI), Office of Infectious Diseases (OID)
OND, CDER, FDA
Silver Spring, MD

Royce Johnson, MD
Medical Director of Valley Fever Institute
Chief of Infectious Disease, Department of Medicine, Kern Medical
Adjunct Professor of Medicine, David Geffen School of Medicine at UCLA
Bakersfield, CA

Laura Kovanda, PhD
Senior Director, Global Development Project Leader
Astellas Pharma Global Development, Inc.
Northbrook, IL

David Larwood, JD
CEO, President
Valley Fever Solutions
Tucson, AZ

Gareth Lewis PhD

Vice President, Specialty Brands
Mayne Pharma
Raleigh, NC

Baoying Liu, PhD, MHS

Program Officer
Bacteriology and Mycology Branch
Division of Microbiology and Infectious Diseases
NIAID, NIH
Bethesda, MD

Shawn Lockhart, PhD

Senior Clinical Laboratory Advisor
Senior Advisor for AMR
Mycotic Diseases Branch
Centers for Disease Control and Prevention
Atlanta, GA

Jason Moore, Pharm.D.

Clinical Pharmacology Reviewer
Division of Infectious Disease Pharmacology (DIDP)
Office of Clinical Pharmacology (OCP)
FDA/CDER/OTS
Silver Spring, MD

Sumathi Nambiar, MD, MPH

Director
DAI, OID
OND, CDER, FDA
Silver Spring, MD

Carmelle Norice-Tra, MD, PhD

Medical Officer, Bacteriology and Mycology Branch
Division of Microbiology and Infectious Diseases
NIAID, NIH
Bethesda, MD

Hanna Oltean, MPH

Zoonotic Disease Epidemiologist
Washington State Department of Health
Seattle, Washington

Elizabeth O’Shaughnessy, MD

Clinical Reviewer
DAI, OID
OND, CDER, FDA
Silver Spring, MD

Luis Ostrosky-Zeichner, MD

Vice-Chair of Medicine
Director of the Laboratory of Mycology Research
McGovern Medical School
Houston, TX

Elektra Papadopoulos, MD, MPH

Associate Director
Clinical Outcome Assessments Staff
OND CDER, FDA
Silver Spring, MD

Peter Pappas, MD

Professor of Medicine
Medicine/Infectious Diseases Department
University of Alabama
Birmingham, AL

Thomas Patterson, MD

Vice-Chair for Faculty Development
Chief, Division of Infectious Diseases
Professor of Medicine
Director, San Antonio Center for Medical Mycology
The University of Texas Health Science Center at San Antonio
San Antonio TX

Rob Purdie

Patient/Program Development Coordinator
Valley Fever Institute
Kern Medical
Bakersfield, CA

John Rex, MD

Chief Medical Officer & Director
F2G, Ltd
Manchester, UK

Lisa Shubitz, DVM

Valley Fever Center for Excellence
The University of Arizona
Tucson, AZ

David A Stevens, MD

Professor (Emeritus) of Medicine
Stanford University Medical School
President of the California Institute for Medical Research
San Jose, CA

George Thompson, MD

Associate Professor of Medicine
Department of Medicine, Division of Infectious Diseases
Department of Medical Microbiology and Immunology
UC-Davis Medical Center
Davis, CA

Julie Tierney, JD

Chief of Staff
Office of Center Director, Center for Biologics Evaluation and Research (CBER)
FDA
Silver Spring, MD

Thomas Walsh, MD, PhD

Founding Director, Transplantation-Oncology Infectious Diseases Program
Chief, Infectious Diseases Translational Research Laboratory
Professor of Medicine, Pediatrics, and Microbiology & Immunology
Weill Cornell Medicine of Cornell University and New York Presbyterian Hospital
Henry Schueler Foundation Scholar
Investigator of Emerging Infectious Diseases of the Save Our Sick Kids Foundation
New York, NY

Nathan Wiederhold, PharmD

Professor, Pathology and Laboratory Medicine
Director, Fungus Testing Laboratory
University of Texas Health Science Center at San Antonio
San Antonio, TX

Erin Zeituni, PhD

Preclinical Services Program Manager
Bacteriology and Mycology Branch
Division of Microbiology and Infectious Diseases
NIAID, NIH
Bethesda, MD

Lanling Zou, MD, PhD
Bacteriology Program Officer
Chief, Translational Sciences Section
Bacteriology and Mycology Branch
Division of Microbiology and Infectious Diseases
NIAID, NIH
Bethesda, MD

Disclosures

David Angulo is an employee of SCYNEXIS, Inc.

Bridget Marie Barker current funding from NIH, State of Arizona and Flinn Foundation.

Erica Easton is a full-time employee of Meridian Healthcare Partners, the management company for the Kern Medical Center Foundation.

David Engelthaler has a minor financial interest in the company Genestat Molecular Devices which holds the license to the FDA-authorized Valley Fever PCR diagnostic assay, which is owned wholly by Translational Genomics Research Institute, Dr. Engelthaler's employer. He is the Director of TGen North, the infectious disease branch of the non-profit Translational Genomics Research Institute.

John Galgiani is a full-time faculty member, University of Arizona College of Medicine-Tucson. He is Chairman of the Board and a significant share-holder of Valley Fever Solutions, Inc. Dr. Galgiani has a conflict of Interest management plan submitted to the University of Arizona.

Edward Garvey is a paid consultant for Mycovia Pharmaceuticals.

Royce H. Johnson is a full-time employee of Kern Medical. He has received travel expenses/honorariums for educational activities and meetings from Horizon Therapeutics. No additional disclosures

Laura Kovanda is a full-time employee of Pharma Company Astellas Pharma Global Development, Inc.

Gareth Lewis is a full-time employee and shareholder of Mayne Pharma.

Kieren Marr is founder and CEO of MycoMed Technologies. Consultant and Advisory Board member for Cidara Therapeutics and Sfunga Therapeutics. She has consulted for Amplyx Pharmaceuticals, Astellas Pharma, Advaxis, Chimerix, F2G Ltd, Genentech, Incyte Corp, Merck

& Co., OncoSec, RTI Surgical, Scynexis, Inc. and Vical. She receives authorship and editorial royalties from UpToDate and a grant from Merck.

Rob Purdie is a contracted employee of the Valley Fever Institute at Kern Medical.

John Rex is Chief Medical Officer & Director, F2G, Ltd.; Operating Partner & Consultant, Advent Life Sciences; and Expert-in-Residence, Wellcome Trust; He sits on the scientific advisory boards of Bugworks Research, Inc.; Basilea Pharmaceutica; Forge Therapeutics, Inc.; Novo Holdings; and Roche Pharma Research & Early Development; He is a shareholder in AstraZeneca Pharmaceuticals; F2G, Ltd; Advent Life Sciences; Macrolide Pharmaceuticals; and Bugworks Research, Inc.; He has received consulting fees from Phico Therapeutics; ABAC Therapeutics; Polyphor, Ltd.; Heptares Therapeutics, Ltd.; Gangagen, Ltd.; Meiji Seika Pharma; Basilea Pharmaceutica International Ltd.; Allecra Therapeutics GmbH; Forge Therapeutics, Inc.; SinSa Labs; AtoxBio; Peptilogics; F. Hoffmann-LaRoche, Ltd.; Novo Holdings; Innocoll; Vedanta; Progenity; Nosopharm SA; Roivant Sciences; and Shionogi Inc.

Lisa Shubitz is a full-time employee of the University of Arizona. Dr. Shubitz' support is from the National Institutes of Health as well as donor funds from the University of Arizona Foundation.

David A. Stevens has recently acted as a consultant to Riptide, Inc.; and recent research contracts held with Riptide, Inc.; Aridis, Inc.; Valley Fever Solutions, Inc. and Ganga Today Trust, and has received speaker fees from Pfizer China.

George R. Thompson, Associate Professor of Medicine has consulted for: Amplyx, Astellas, Cidara, F2G, Mayne, Vical. DSMB for Pfizer. Research support from: Amplyx, Astellas, Cidara, F2G, Gilead, Mayne, Merck, Regeneron, Vir

Thomas Walsh has received grants for experimental and clinical antimicrobial pharmacology and therapeutics to his institution from Allergan, Amplyx, Astellas, Lediand, Medicines Company, Merck, Scynexis, and Tetrphase and has served as consultant to Amplyx, Astellas, Allergan, ContraFect, Gilead, Lediand, Medicines Company, Merck, Methylgene, Pfizer, and Scynexis.

Nathan Wiederhold, Research support (to UT Health Science Center San Antonio) from Astellas, bioMerieux, Cepheid, Covance, F2G, Sfunga, and Viamet. Advisory board member for Mayne Pharma, Speakers Bureau for Gilead.

Luis Ostrosky-Zeichner has received research funding and/or personal honoraria for consulting or speaking from Pfizer, Merck, Astellas, Cidara, Scynexis, F2G, Amplyx, Gilead, Therapeutics, Inc, Viracor, Octapharma, Biotoscana, Stendhal, Mayne, Takeda, RealTime labs, and Viracor.